These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 28097847)
1. [Nicolau syndrome induced by intramuscular injection of a hexavalent vaccine in a 6-month-old girl]. Stefano PC; Garello M; Nolte MF; Lamy P; Giglio N; Castellano V; Gentile Á Arch Argent Pediatr; 2017 Feb; 115(1):e13-e16. PubMed ID: 28097847 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596 [TBL] [Abstract][Full Text] [Related]
3. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958 [TBL] [Abstract][Full Text] [Related]
4. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924 [TBL] [Abstract][Full Text] [Related]
5. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Posuwan N; Wanlapakorn N; Vongpunsawad S; Sintusek P; Leuridan E; Van Damme P; Poovorawan Y Vaccine; 2020 Feb; 38(7):1643-1651. PubMed ID: 31948817 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R; Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582 [TBL] [Abstract][Full Text] [Related]
12. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines. Dolhain J; Janssens W; Dindore V; Mihalyi A Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine. Knutsson N; Trollfors B; Taranger J; Bergfors E; Sundh V; Lagergård T; Ostergaard E; Cicirello H; Käyhty H Vaccine; 2001 Aug; 19(31):4396-403. PubMed ID: 11483264 [TBL] [Abstract][Full Text] [Related]
15. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Lim FS; Han HH; Jacquet JM; Bock HL Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229 [TBL] [Abstract][Full Text] [Related]
16. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Silfverdal SA; Icardi G; Vesikari T; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW Vaccine; 2016 Jul; 34(33):3810-6. PubMed ID: 27288217 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322 [TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054 [TBL] [Abstract][Full Text] [Related]
19. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383 [TBL] [Abstract][Full Text] [Related]
20. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Avdicova M; Crasta PD; Hardt K; Kovac M Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]